King's College London

Research portal

Predictive value of cardiometabolic biomarkers and depressive symptoms for symptom severity and quality of life in patients with psychotic disorders

Research output: Contribution to journalArticlepeer-review

Cecilia Serrano de Haro Perez, Simone Ciufolini, Poonam Gardner Sood, Amir Krivoy, Allan H Young, Robin M Murray, Khalida Ismail, Zerrin Atakan, Kathryn Greenwood, Shubulade Smith, Fiona Gaughran, Mario F Juruena

Original languageEnglish
Pages (from-to)95-103
Number of pages9
JournalJournal of Affective Disorders
Volume298
Early online date8 Nov 2021
DOIs
E-pub ahead of print8 Nov 2021
Published1 Feb 2022

Bibliographical note

Funding Information: This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its IMPACT Programme (Grant Reference Number RP-PG- 0606–1049) in collaboration with Genetics and Psychosis Project funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. FG is in part supported by the National Institute for Health Research’s (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Maudsley Charity and the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. Professor Young's research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Dr Juruena's independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London Maudsley NHS Foundation Trust (SLaM), King's College London and SLaM. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, or the Department of Health and Social Care. Funding Information: This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its IMPACT Programme (Grant Reference Number RP-PG- 0606?1049) in collaboration with Genetics and Psychosis Project funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. FG is in part supported by the National Institute for Health Research's (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Maudsley Charity and the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. Professor Young's research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Dr Juruena's independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London Maudsley NHS Foundation Trust (SLaM), King's College London and SLaM. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, or the Department of Health and Social Care. Publisher Copyright: © 2021

King's Authors

Abstract

BACKGROUND: Patients with psychotic disorders show higher rates of the metabolic syndrome (MS) between the cluster of severe mental illnesses. Depressive symptoms can worsen outcomes of individuals with psychotic disorders. However, research on the association between MS and depression in psychotic disorders and their relevance to outcomes is lacking.

METHODS: We investigated the association between depression and cardiometabolic biomarkers in psychotic disorders and the predictive value of depressive symptoms on psychopathological severity and quality of life (QoL). 406 patients with psychotic disorders were recruited as part of the Improving Physical Health and Reducing Substance Use in Severe Mental Illness randomised controlled trial. Depression, psychotic symptoms, QoL, waist circumference, triglycerides, high-density lipoprotein cholesterol (HDL-C), blood pressure, and fasting glucose of patients were assessed at baseline and 12 months. Sensitivity analyses were conducted to test the effect of treatment.

RESULTS: More severe baseline symptoms of depression significantly predicted worse 12-month psychotic symptoms and lower mental health related QoL at 12 months. These associations held after controlling for alcohol use, gender, ethnicity, education, and mental health related QoL Baseline. Depressive symptoms also correlated with waist circumference at both baseline and 12 months, after controlling for multiple testing.

CONCLUSION: Individuals with psychotic disorders experiencing more severe depressive symptoms are more likely to have larger waist circumference contemporaneously and 12 months later, as well as more severe psychotic symptoms and worse QoL at follow-up. This highlights the need for evaluation of strategies to address depression in the management of psychotic disorders.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454